Asset 1.png

Nadia Dahmane

Weill Cornell Medicine
New York, NY, USA

CBTN Specimen


CBTN Participants

CBTN Pre-clinical Models


Internal funding

About this


Atypical teratoid rhabdoid tumor (ATRT) is a common and hard to treat form of pediatric brain cancer. Despite current therapy options including aggressive chemotherapy, radiation, and stem cell transplant, the overall survival rate of ATRT patients is still low. To better treat this disease, researchers must better understand its genetic and molecular characteristics. Researchers have identified genetic alterations that are hallmarks of ATRT. Mutations in a gene named SMARCB1 may lead cells to act like stem cells and become cancerous. Researchers have also identified the transcription factor RP58 (aka ZBTB18) as an essential regulator of brain development. Experiments have been performed to better understand the potential impact on ATRTs. The overall research hypothesis is that RP58 acts with SMARCB1 to control brain development and that disruption of this interaction leads to defects in this process that results in ATRTs. The Children’s Brain Tumor Network provides researchers with the rare ATRT cell lines necessary to complete this work. Understanding the role and regulation of SMARCB1 during early brain development is critical to not only a better understanding of AT/RT tumors but also to the development of novel therapies for this aggressive tumor.

Ask The


Ask the scientists

What are the goals of this project?

The goals of this project involve understanding the interactions between SMARCB1 and transcription factor RP58 and how they affect the development of ATRTs.

What is the impact of this project?

With a deeper understanding of genetic and molecular interactions, researchers may uncover important avenues for new therapies.

Why is the CBTN request important to this project?

This research requires rare and high quality specimens like those made available through the Children’s Brain Tumor Network.